Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYFAVO vs ONFI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Improvement of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA) as an adjunct to upper airway stimulation therapy
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein.
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration.
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally).
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established.
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended.
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
Not approved for pediatric patients <18 years of age. Safety and efficacy not established.
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia.
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.,May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.,Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.,Potential for drug interactions with strong CYP3A4 inhibitors or inducers.,May cause insomnia, anxiety, or restlessness.
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
Hypersensitivity to BYFAVO or any of its components,Severe hepatic impairment (Child-Pugh Class C)
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
No pharmacokinetic data in pregnancy; standard dosing is not recommended as drug is contraindicated. If use is unavoidable, no specific dose adjustment guidelines exist; use with extreme caution and consider alternative therapy.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly.
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse.,Do not consume alcohol for at least 24 hours after sedation.,You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home.,Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYFAVO vs ONFI, answered by our medical review team.
BYFAVO is a Benzodiazepine that works by Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.. ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYFAVO and ONFI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYFAVO is: For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.. The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYFAVO and ONFI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYFAVO is classified as Category C. BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.